Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Fulbright

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Mechanisms of Ageing and Development|August 28, 1998
Functional properties of CD4+ CD28- T cells in the aging immune systemC M Weyand, J C Brandes, D Schmidt, et al.
Archives of Internal Medicine|March 25, 1999
Corticosteroid requirements in polymyalgia rheumaticaC M Weyand, J W Fulbright, J M Evans, et al.
Arthritis and Rheumatism|May 19, 2000
Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activityC M Weyand, J W Fulbright, G G Hunder, et al.
Human Immunology|December 1, 1995
HLA-DRB1 molecules and antigenic experience shape the repertoire of CD4 T cellsD R Walser-Kuntz, C M Weyand, J W Fulbright, et al.
Journal of Virology|November 17, 2001
Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individualsJ J Goronzy, J W Fulbright, C S Crowson, et al.
Arthritis and Rheumatism|September 1, 1993
Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritisN E Roche, J W Fulbright, A D Wagner, et al.
Rheumatology (Oxford, England)|February 26, 2004
How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trialE L Matteson, C M Weyand, J W Fulbright, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Mechanisms of Ageing and Development|August 28, 1998
Functional properties of CD4+ CD28- T cells in the aging immune systemC M Weyand, J C Brandes, D Schmidt, et al.
Archives of Internal Medicine|March 25, 1999
Corticosteroid requirements in polymyalgia rheumaticaC M Weyand, J W Fulbright, J M Evans, et al.
Arthritis and Rheumatism|May 19, 2000
Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activityC M Weyand, J W Fulbright, G G Hunder, et al.
Human Immunology|December 1, 1995
HLA-DRB1 molecules and antigenic experience shape the repertoire of CD4 T cellsD R Walser-Kuntz, C M Weyand, J W Fulbright, et al.
Journal of Virology|November 17, 2001
Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individualsJ J Goronzy, J W Fulbright, C S Crowson, et al.
Arthritis and Rheumatism|September 1, 1993
Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritisN E Roche, J W Fulbright, A D Wagner, et al.
Rheumatology (Oxford, England)|February 26, 2004
How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trialE L Matteson, C M Weyand, J W Fulbright, et al.
Pageof 1